// App-Quantinova.ai

P590 : An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab

Researchers

Presenter

  • B Bokemeyer

Principal Investigators

  • T Hlavaty

  • M Allez

  • P Selema

  • S Moosavi

  • M J Cadatal

  • H Fowler

  • R Cheung

  • M Lukas

  • J P Gisbert

Medical Centers

  • Gastroenterology Practice, Minden, Germany

  • University Hospital Bratislava and Comenius University, Bratislava, Slovakia

  • AP-HP - Hôpitaux Univ Saint-Louis-Lariboisière-Fernand-Widal, Paris, France

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Makati, Philippines

  • Pfizer Inc., Maidenhead, UK

  • IBD Clinical and Research Centre, ISCARE IVF and 1st Medical Faculty, Charles University, Prague, Czech Republic

  • Hospital Universitario La Princesa – ISS-IP, Madrid, Spain

Locations

  • Germany

  • Slovakia

  • France

  • United States

  • Philippines

  • United Kingdom

  • Czech Republic

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved